Rheos: applying immune cell reprogramming to autoimmunity

How Rheos is applying immunometabolism to autoimmunity to uncover personalized treatments

As immune cell reprogramming is gaining traction in immuno-oncology, Rheos is applying the concept to autoimmune diseases with a platform that can pinpoint metabolic targets in immune cells to control their phenotype and function.

The company coupled two hot topics on the radar of many pharma companies -- immunometabolism and precision autoimmunity -- and engaged potential partners from the outset to attract its first major deal less than two years after launch.

On Dec. 19, Rheos Medicines

Read the full 761 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE